alendronate sodium

(redirected from Dom-Alendronate)

alendronate sodium

Apo-Alendronate (CA), Co Alendronate (CA), Dom-Alendronate (CA), Fosamax, Gen-Alendronate (CA), Ratio-Alendronate (CA), Sandoz Alendronate

Pharmacologic class: Bisphosphonate

Therapeutic class: Bone-resorption inhibitor

Pregnancy risk category C


Impedes bone resorption by inhibiting osteoclast activity, absorbing calcium phosphate crystal in bone, and directly blocking dissolution of hydroxyapatite crystal of bone


Tablets: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg

Indications and dosages

Paget's disease of bone (men and women)

Adults: 40 mg P.O. daily for 6 months

Prevention of osteoporosis in postmenopausal women

Adults: 5 mg P.O. daily or 35 mg P.O. once weekly for up to 7 years

Glucocorticoid-induced osteoporosis in men and women

Adults: 5 mg P.O. daily. For postmenopausal women not receiving estrogen, recommended dosage is 10 mg P.O. once daily.

Treatment of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis

Adults: 70-mg tablet or 70 mg oral solution P.O. weekly or 10-mg tablet P.O. daily


• Hypersensitivity to drug or its components
• Hypocalcemia
• Esophageal abnormalities such as stricture or achalasia that delay esophageal emptying
• Inability to stand or sit upright for 30 minutes
• Increased risk of aspiration (oral solution)


Use cautiously in:
• Severe renal insufficiency (creatinine clearance less than 35 ml/minute), esophageal disease, GI ulcers, gastritis, osteonecrosis of jaw
• pregnant or breastfeeding patients
• children.


• Give with 6 to 8 oz of water 30 minutes before first food, beverage, or medication of day.
• Don't give at bedtime or before patient arises for the day.
• Don't give food, other beverages, or oral drugs for at least 30 minutes after giving tablets.
• Keep patient upright for at least 30 minutes after giving dose to avoid serious esophageal irritation.
• Follow oral solution with at least 60 ml (2 oz) of water to facilitate gastric emptying.
• Be aware that patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
• Be aware that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may worsen GI upset. Discuss alternative analgesics with prescriber.

Adverse reactions

CNS: headache

CV: hypertension

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, acid regurgitation, esophageal ulcer, flatulence, dyspepsia, abdominal distention, dysphagia

GU: urinary tract infection

Hematologic: anemia

Metabolic: hypomagnesemia, hypophosphatemia, hypokalemia, fluid overload

Musculoskeletal: bone or muscle pain

Skin: rash, redness, photosensitivity

Other: abnormal taste


Drug-drug.Antacids, calcium supplements: decreased alendronate absorption

NSAIDs, salicylates: increased risk of GI upset

Ranitidine: increased alendronate effect

Drug-diagnostic tests.Calcium, phosphate: decreased levels

Drug-food.Any food, caffeine (as in coffee, tea, cocoa), mineral water, orange juice: decreased drug absorption

Patient monitoring

• Monitor for signs and symptoms of GI irritation, including ulcers.
• Monitor blood pressure.
• Evaluate blood calcium and phosphate levels.

Patient teaching

Tell patient to immediately report serious vomiting, severe chest or abdominal pain, difficulty swallowing, or abdominal swelling.
• Instruct patient to take tablets first thing in the morning on an empty stomach, with 6 to 8 oz of water only.
• Instruct patient to follow oral solution with at least 60 ml (2 oz) of water.
• Tell patient not to lie down, eat, drink, or take other oral medications for 30 minutes after taking dose.
• Advise patient to take only those pain relievers suggested by prescriber. Inform him that some over-the-counter pain medications (such as aspirin and NSAIDs) may worsen drug's adverse effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

alendronate sodium (əlen´drənāt´ sō´dēəm),

n brand name: Fosamax;
drug class: amino biphosphonate;
action: acts as a specific inhibitor of bone resorption;
uses: osteoporosis in postmenopausal women, Paget's disease of bone.
Mentioned in ?